A post hoc analysis of two randomized clinical trials shows some evidence that taking statins and vitamin D supplements might reduce the risk of death in men who have castrate resistant prostate cancer (CRPC) who are also taking the drug Zytiga (abiraterone acetate or AA) with prednisone.

There have been observational studies reporting that adding statins to Zytiga and prednisone may boost the antitumor activity of the Zytiga, possibly improving the Zytiga’s efficacy. Conclusions about adding vitamin D are less clear, but a possible benefit has been described in other literature

Researchers performed a post hoc analysis of individual patient data from two randomized clinical trials of men who had castrate resistant prostate cancer and who took Zytiga with prednisone and/or statins or vitamin D.

In the COU-AA-301 trial, the use of Zytiga with statin and vitamin D reduced the risk of death by 38% (p = 0.0007) while Zytiga alone was associated with a decrease of 10% (p = 0.025), compared to prednisone alone.

In the COU-AA-302 trial, the use of Zytiga plus statin plus vitamin D was associated with a reduced risk of death of 26% (p = 0.0054).

In this data analysis from two prospective randomized clinical trials, statin and vitamin D use was associated with superior overall survival in men with metastatic CRPC who were treated with Zytiga and prednisone. Cancer ABCs believe that these data support asking your doctor if you should be adding a statin and or vitamin D to your Zytiga treatment protocol.

pubmed.ncbi.nlm.nih.gov/321...

PMID: 32198642 DOI: 10.1007/s12094-020-02334-6